Lyra Therapeutics (LYRA) Return on Invested Capital (2023 - 2025)
Lyra Therapeutics (LYRA) has disclosed Return on Invested Capital for 3 consecutive years, with 26.11% as the latest value for Q3 2025.
- On a quarterly basis, Return on Invested Capital rose 3004.0% to 26.11% in Q3 2025 year-over-year; TTM through Sep 2025 was 26.11%, a 3004.0% increase, with the full-year FY2024 number at 1.91%, down 112.0% from a year prior.
- Return on Invested Capital was 26.11% for Q3 2025 at Lyra Therapeutics, up from 15.12% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 26.11% in Q3 2025 to a low of 15.12% in Q2 2025.
- A 3-year average of 1.64% and a median of 2.94% in 2024 define the central range for Return on Invested Capital.
- Biggest YoY gain for Return on Invested Capital was 3004bps in 2025; the steepest drop was -1317bps in 2025.
- Lyra Therapeutics' Return on Invested Capital stood at 0.77% in 2023, then plummeted by -673bps to 5.98% in 2024, then soared by 536bps to 26.11% in 2025.
- Per Business Quant, the three most recent readings for LYRA's Return on Invested Capital are 26.11% (Q3 2025), 15.12% (Q2 2025), and 10.56% (Q1 2025).